| Bioactivity | Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3]. |
| Target | P-selectin |
| In Vivo | Crizanlizumab (1 或 6 mg/kg，腹膜内注射，每周 3 天，持续 5 个月) 可改善 4 周龄雄性 HbSS (镰状细胞病) 小鼠的镰状细胞性视网膜病变[3]。 |
| Name | Crizanlizumab |
| CAS | 1690318-25-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020). [2]. Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. [3]. Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747. |